Publications by authors named "Carolina T Ribeiro"
Article Synopsis
- The study investigated the effectiveness of N-acetylcysteine (NAC) in relieving dryness symptoms in women with Sjögren's disease through a placebo-controlled trial with 60 participants.
- Results showed no significant improvements in dryness symptoms or oxidative stress levels with NAC compared to placebo at the 30 and 90-day marks, despite higher NAC blood concentrations in the treatment group.
- The findings suggest that while NAC can be taken as a rescue therapy for Sjögren's disease, it does not significantly alleviate symptoms of dryness or oxidative stress.
Hydroxychloroquine (HCQ) has been used to treat Sjögren's disease (SjD) patients. However, there are no studies evaluating drug adherence through HCQ blood levels, pharmacy refill (PR) and medication adherence questionnaires. The relationship of HCQ blood levels with glandular/extraglandular disease parameters was also poorly assessed.
View Article and Find Full Text PDFPost-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition.
Adv Rheumatol
June 2023
Article Synopsis
- A study evaluated post-acute COVID-19 in vaccinated patients with autoimmune rheumatic diseases (ARD) compared to non-ARD controls, finding similarities in the frequency and symptoms of the condition between both groups.
- The study involved 108 ARD patients and 32 non-ARD controls, all diagnosed with COVID-19 after receiving the third dose of the CoronaVac vaccine, and utilized established international diagnostic criteria for post-acute COVID-19.
- Results indicated that factors like age, sex, and disease severity did not significantly affect the incidence of post-acute symptoms, which were predominantly fatigue and memory loss in both ARD and non-ARD patients.
Objective: Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19.
View Article and Find Full Text PDFIncrement of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Ann Rheum Dis
July 2022
Objective: To determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response.
Methods: Adult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240).
The objective of this study is to assess the role of the 2019-European League Against Rheumatism/American College of Rheumatology (2019-EULAR/ACR) classification criteria at diagnosis and its domains in predicting long-term damage in systemic lupus erythematosus(SLE). We performed a retrospective analysis using an electronic chart database utilized in routine clinical care of SLE patients and established in 2000 in a tertiary hospital. Two hundred and nine consecutive SLE patients with disease onset ≥18 years old and long disease duration were included.
View Article and Find Full Text PDFCoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no.
View Article and Find Full Text PDF